Literature DB >> 10934729

Influence of peroxide impurities in povidone and crospovidone on the stability of raloxifene hydrochloride in tablets: identification and control of an oxidative degradation product.

K J Hartauer1, G N Arbuthnot, S W Baertschi, R A Johnson, W D Luke, N G Pearson, E C Rickard, C A Tingle, P K Tsang, R E Wiens.   

Abstract

The purpose of this study was to identify a degradation product in a tablet formulation of raloxifene hydrochloride (R-HCl), delineate the role of excipients in its formation, and develop a rational strategy for its control. The degradant was identified as an N-oxide derivative of the drug substance based upon spectroscopic characterization and chromatographic comparison to the synthetic N-oxide. To identify the factors contributing to the formation of N-oxide, binary mixtures of each excipient with R-HCl were exposed to 125 degrees C in open containers. Raloxifene hydrochloride underwent an order of magnitude increase in conversion to the N-oxide in the presence of two excipients, povidone and crospovidone, as compared with its conversion in the presence of other excipients. To confirm a hypothesis that peroxide impurities in these two excipients contributed to the oxidation of the drug substance, tablet lots were spiked with quantities of H2O2 equivalent to 200, 400, 600, and 800 ppm peroxide over the intrinsic levels present in povidone and crospovidone. A strong correlation was observed between the total peroxide level and the quantity of the N-oxide formed upon accelerated storage. From these experiments a rational limit test for peroxide content in povidone and crospovidone was adopted as part of a control strategy to limit formation of the degradation product.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10934729     DOI: 10.1081/pdt-100100545

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  11 in total

Review 1.  Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.

Authors:  Yongmei Wu; Jaquan Levons; Ajit S Narang; Krishnaswamy Raghavan; Venkatramana M Rao
Journal:  AAPS PharmSciTech       Date:  2011-09-27       Impact factor: 3.246

Review 2.  Impact of excipient interactions on solid dosage form stability.

Authors:  Ajit S Narang; Divyakant Desai; Sherif Badawy
Journal:  Pharm Res       Date:  2012-06-16       Impact factor: 4.200

3.  Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 1: Predicting degradation related impurities and impurity considerations for pharmaceutical dosage forms.

Authors:  Karen M Alsante; Kim Huynh-Ba; Steven W Baertschi; Robert A Reed; Margaret S Landis; Mark H Kleinman; Christopher Foti; Venkatramana M Rao; Paul Meers; Andreas Abend; Daniel W Reynolds; Biren K Joshi
Journal:  AAPS PharmSciTech       Date:  2013-11-27       Impact factor: 3.246

4.  Mechanism of the solution oxidation of rofecoxib under alkaline conditions.

Authors:  Paul A Harmon; Stephen Biffar; Steven M Pitzenberger; Robert A Reed
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

5.  Polymeric systems for amorphous Delta9-tetrahydrocannabinol produced by a hot-melt method. Part II: Effect of oxidation mechanisms and chemical interactions on stability.

Authors:  Manish Munjal; Mahmoud A Elsohly; Michael A Repka
Journal:  J Pharm Sci       Date:  2006-11       Impact factor: 3.534

6.  Mechanism of Decarboxylation of Pyruvic Acid in the Presence of Hydrogen Peroxide.

Authors:  Antonio Lopalco; Gautam Dalwadi; Sida Niu; Richard L Schowen; Justin Douglas; Valentino J Stella
Journal:  J Pharm Sci       Date:  2016-01-29       Impact factor: 3.534

7.  Systematical approach in evaluation of LC method for determination of raloxifene hydrochloride and its impurities employing experimental design.

Authors:  B Jančić Stojanović; T Rakić; B Slavković; N Kostić; A Vemić; A Malenović
Journal:  J Pharm Anal       Date:  2012-10-07

Review 8.  Oxidation of Drugs during Drug Product Development: Problems and Solutions.

Authors:  Alen Gabrič; Žiga Hodnik; Stane Pajk
Journal:  Pharmaceutics       Date:  2022-01-29       Impact factor: 6.321

9.  In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance.

Authors:  Osama Aa Ahmed; Shaimaa M Badr-Eldin
Journal:  Int J Nanomedicine       Date:  2018-10-11

10.  Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene.

Authors:  Nabil A Alhakamy; Usama A Fahmy; Osama A A Ahmed
Journal:  PLoS One       Date:  2019-12-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.